|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||27.07 - 27.52|
|52 Week Range||25.40 - 55.95|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2018 - Mar 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||49.18|
The Medicines Company today announced that it will host an Investor Day on Tuesday, January 23, 2018, from 10:00 a.m. to 12:30 p.m., Eastern Time, in New York City.
Sarissa Capital Management last week made nearly $15 million in stock purchases. Sarissa, a hedge fund that specializes in drug developers, added to positions in Biogen (BIIB) and Medicines (MDCO). On Nov. 28 and 29 the fund bought 30,000 shares of Biogen for $9.52 million, or $317.36 each.
NEW YORK, Dec. 01, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Lannett ...
Stock Monitor: Medicines Co. Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 01, 2017 / Active-Investors issued a free report on Melinta Therapeutics, Inc. (NASDAQ: MLNT ) ("Melinta"), ...
The Medicine Company (MDCO) has signed an agreement with Melinta to sell its infectious disease unit in a cash and stock transaction.
Shares of Medicines Co. dove to a 21-month low after the biotech sold its infectious diseases unit for $270 million.
The Medicines Co. said Wednesday it has agreed to sell its infectious disease unit to Melinta Therapeutics Inc. for $270 million in upfront consideration, guaranteed payments of $215 million in cash and ...
NEW YORK, Nov. 29, 2017 /PRNewswire/ -- Deerfield Management Company announced today it has committed to provide up to $240 million in debt and equity financing to Melinta Therapeutics (MLNT) and up to $100 million in debt financing to The Medicines Company (MDCO) in connection with Melinta's acquisition of the infectious disease business from The Medicines Company. The acquisition includes the purchase of global rights for Vabomere, Orbactiv and Minocin IV and the business unit supporting those products. Upon the closing of the acquisition, Deerfield will provide $190 million in debt and equity funding to Melinta. Furthermore, Melinta will have the option to draw up to $50 million of debt within 24 months of the closing of the transaction subject to achieving certain sales thresholds. In addition, Deerfield has agreed to provide up to $100 million in drawable debt financing to The Medicines Company.
The Medicines Company today announced that it has entered into a definitive agreement to sell its infectious disease business unit to Melinta Therapeutics, Inc. for $270 million in upfront consideration and guaranteed payments , tiered royalty payments of 5% to 25% on worldwide net sales of Vabomere™, Orbactiv® and Minocin IV, and the assumption by Melinta of all royalty, milestone and other payment ...
-Acquisition positions Melinta as durable and focused pure-play antibiotics company with four marketed products: Baxdela ®, Vabomere ®, Orbactiv ®, and Minocin IV ®-. -Peak sales potential of the portfolio ...
Research Desk Line-up: Nature's Sunshine Products Post Earnings Coverage LONDON, UK / ACCESSWIRE / November 21, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on The Medicines ...
The Medicines Company today announced that its Board of Directors has appointed Fredric N. Eshelman, PharmD., the Company’s current Chairman of the Board, to the newly created position of Executive Chairman, and Geno Germano, a pharmaceutical industry executive with over 30 years of leadership experience, as a new, independent Director of the Company.
The Medicines Company (MDCO) needs investors to pay close attention to the stock based on moves in the options market lately.
The Medicines Company (MDCO) incurs loss in the third quarter of 2017. The top line decreases year over year due to low Angiomax sales.
The Medicines Company today reported its financial results for the third quarter ended September 30, 2017, and provided an update on its clinical and operational activities.
The Medicines Company will host a conference call on Wednesday, October 25, 2017, at 8:30 a.m., Eastern Time, to discuss its third-quarter 2017 financial results and operational developments.
On August 29, 2017, the FDA approved The Medicines Company’s (MDCO) Vabomere for treating adulating patients suffering with complicated urinary tract infections.
On August 28, 2017, The Medicines Company (MDCO) announced positive data from its Phase 2 trial, ORION-1, evaluating the efficacy of PCSK9 synthesis inhibitor inclisiran.
In 2Q17, The Medicines Company (MDCO) reported a net loss from continuing operations of $397.3 million, which was a significant fall from $181.8 million in 2Q16.
In 2Q17, The Medicines Company (MDCO) reported revenues of $18.7 million, which is a fall of 66.0% on a YoY (year-over-year) basis.
The Medicines Company today announced that new data from its TANGO II study of VABOMERE will be presented this week at IDWeek 2017 in San Diego.